Table 1.
Baseline demographics & disease characteristics
| Characteristic | UltIMMa‐1 and UltIMMa‐2 | LIMMitless | |
|---|---|---|---|
|
UST n = 199 |
RZB n = 598 |
RZB n = 525 |
|
| Age, years, mean (SD) | 47.5 (14.1) | 47.2 (13.6) | 47.7 (13.32) |
| Male, n (%) | 136 (68.3) | 415 (69.4) | 364 (69.3) |
| Race, white, n (%) | 165 (82.9) | 455 (76.1) | 393 (74.9) |
| Weight, kg, mean (SD) | 90.4 (22.2) | 90.0 (22.4) | 89.9 (22.13) |
| Weight >100 kg, n (%)† | 56 (28.1) | 169 (28.3) | 149 (28.4) |
| BMI, kg/m2, mean (SD) | 30.4 (6.8) | 30.5 (7.0) | 30.4 (6.83) |
| PASI, mean (SD) | 19.2 (6.4) | 20.6 (7.7) | 20.4 (7.63) |
| sPGA of severe, n (%) | 33 (16.6) | 114 (19.1) | 101 (19.2) |
| BSA, %, mean (SD) | 23.0 (13.6) | 26.2 (15.6) | 25.8 (15.41) |
| Psoriatic arthritis status, n (%)† | 50 (25.1) | 159 (26.6) | 143 (27.2) |
| Any prior biologic therapy, n (%) | 73 (36.7) | 222 (37.1) | 196 (37.3) |
| Prior TNFi, n (%)† | 43 (21.6) | 134 (22.4) | 119 (22.7) |
| Prior IL‐17i, n (%) | 35 (17.6) | 111 (18.6) | 95 (18.1) |
BMI, body mass index; BSA, body surface area; IL‐17i, interleukin‐17 inhibitor; PASI, Psoriasis Area and Severity Index; RZB, risankizumab; SD, standard deviation; sPGA, static Physician’s Global Assessment; TNFi, tumor necrosis factor inhibitor; UST, ustekinumab.
†
Randomisation was stratified by weight (≤100 kg or >100 kg) and prior TNFi exposure. ‡Diagnosed or suspected psoriatic arthritis.